Cargando…

Analysis of pemetrexed-based chemotherapy in the treatment of advanced colorectal cancer

BACKGROUND: In this study, we evaluated the therapeutic efficacy and toxicity profile of chemotherapy combinations containing pemetrexed for patients with metastatic colorectal cancer. We investigated the optimal chemotherapy treatment regimen to provide a new option for third-line or after treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Zhengyi, Wang, Jiawei, Cai, Xiaomin, Gao, Zhenzhen, Wang, Sailan, Gu, Yanhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723524/ https://www.ncbi.nlm.nih.gov/pubmed/33313113 http://dx.doi.org/10.21037/atm-20-1095

Ejemplares similares

Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer
por: Jo, Jaemin, et al.
Publicado: (2018)

Rechallenge pemetrexed-based chemotherapy provides an option for initially benefited patients with advanced lung adenocarcinoma
por: Wang, Jia-Ni, et al.
Publicado: (2021)

Comparison of different chemoradiotherapy regimens for the preoperative treatment in patients with locally advanced rectal cancer: a network meta-analysis
por: Yu, Zhengyi, et al.
Publicado: (2020)

Blood T cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapy
por: Qian, Li, et al.
Publicado: (2021)

Uric acid preconditioning alleviated doxorubicin induced JNK activation and Cx43 phosphorylation associated cardiotoxicity via activation of AMPK-SHP2 signaling pathway
por: Wang, Jiawei, et al.
Publicado: (2020)

Association between TYMS Expression and Efficacy of Pemetrexed–Based Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
por: Wang, Ting, et al.
Publicado: (2013)

Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
por: Lin, Zhong, et al.
Publicado: (2017)

Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma
por: Guo, Long-Hua, et al.
Publicado: (2020)

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
por: Wang, Yan, et al.
Publicado: (2018)

Pemetrexed-based first-line chemotherapy had particularly prominent objective response rate for advanced NSCLC: A network meta-analysis
por: Lv, Yuankai, et al.
Publicado: (2021)

Single pemetrexed is noninferior to platinum-based pemetrexed doublet as first-line treatment on elderly Chinese patients with advanced nonsquamous nonsmall cell lung cancer
por: Pu, Xiaolin, et al.
Publicado: (2017)

Comprehensive Analysis of lncRNA–miRNA– mRNA Network Ascertains Prognostic Factors in Patients with Colon Cancer
por: Gao, Zhenzhen, et al.
Publicado: (2019)

Prognostic value of serum leptin in advanced lung adenocarcinoma patients with cisplatin/pemetrexed chemotherapy
por: MOU, WENJUN, et al.
Publicado: (2014)

Epiphora following chemotherapy with pemetrexed in patients with advanced non-small cell lung cancer
por: Jung, Yun Duk, et al.
Publicado: (2017)

High plasma exposure to pemetrexed leads to severe hyponatremia in patients with advanced non small cell lung cancer receiving pemetrexed-platinum doublet chemotherapy
por: Gota, Vikram, et al.
Publicado: (2014)

MTAP-deficiency could predict better treatment response in advanced lung adenocarcinoma patients initially treated with pemetrexed-platinum chemotherapy and bevacizumab
por: Jing, Wang, et al.
Publicado: (2020)

Significant Clinical Benefit of Pemetrexed-based Chemotherapy for Advanced Diffuse Malignant Peritoneal Mesothelioma: A Case Presentation
por: Peitl, Milena, et al.
Publicado: (2017)

Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma
por: Wang, Lin, et al.
Publicado: (2017)

The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis
por: Zhong, Anyuan, et al.
Publicado: (2015)

Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China
por: Lu, Shun, et al.
Publicado: (2016)

Association between BRAF mutant classification and the efficacy of pemetrexed-based chemotherapy in Chinese advanced non-small cell lung cancer patients: a multicenter retrospective study
por: Lei, Lei, et al.
Publicado: (2020)

Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting
por: Li, Jianjie, et al.
Publicado: (2021)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
por: Blais, Normand, et al.
Publicado: (2014)

Anti-Angiogenic Effect of Orally Available Pemetrexed for Metronomic Chemotherapy
por: Maharjan, Ruby, et al.
Publicado: (2019)

Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules
por: Li, K M, et al.
Publicado: (2007)

Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study
por: Xu, Chun-Wei, et al.
Publicado: (2020)

Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement
por: Zhang, Limin, et al.
Publicado: (2016)

Erratum: Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
Publicado: (2014)

Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial
por: Lim, Sung Won, et al.
Publicado: (2018)

Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial
por: Wang, Huijuan, et al.
Publicado: (2020)

Computed Tomography Image under Artificial Intelligence Algorithm to Evaluate the Nursing and Treatment Effect of Pemetrexed Combined Platinum-Based Chemotherapy on Elderly Lung Cancer
por: Gu, Qing, et al.
Publicado: (2022)

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
por: Takeyasu, Yuki, et al.
Publicado: (2022)

Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
por: Zhai, Xiaoyu, et al.
Publicado: (2017)

Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer
por: Russo, Francesca, et al.
Publicado: (2008)

Pemetrexed/cisplatin as first-line chemotherapy for advanced lung cancer with brain metastases: A case report and literature review
por: He, Guangzhao, et al.
Publicado: (2016)

Prediction of response and adverse drug reaction of pemetrexed plus platinum-based chemotherapy in lung adenocarcinoma by serum metabolomic profiling
por: Gong, Wei-Jing, et al.
Publicado: (2022)

Renal failure during chemotherapy: renal biopsy for assessing subacute nephrotoxicity of pemetrexed
por: Assayag, Maureen, et al.
Publicado: (2017)

Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer
por: Minami, Seigo, et al.
Publicado: (2015)

Phase I study of pemetrexed with sorafenib in advanced solid tumors
por: Poklepovic, Andrew, et al.
Publicado: (2016)

A single-arm, prospective study of apatinib mesylate plus pemetrexed in patients of advanced non-squamous non-small cell lung cancer after failure of previous chemotherapy
por: Dong, Shuang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l0mssfhln1qm0bi70mhibrn82h